Immuno-Oncology Diagnostics: The Race for Biomarkers Market to 2024

News provided by

Nov 14, 2019, 08:15 ET

DUBLIN, Nov. 14, 2019 /PRNewswire/ -- The "Immuno-Oncology Diagnostics The Race for Biomarkers Market Forecasts for Immuno-Oncology Diagnostics, With Executive and Consultant Guides and including Customized Forecasting and Analysis - 2020 to 2024" report has been added to ResearchAndMarkets.com's offering.

Revolution in cancer therapy to be driven by new diagnostics. Histology, genomics and liquid biopsy converge.

This is a complex area but this readable report will bring the entire management team up to speed, on both the technology and the opportunity.

A revolution in cancer therapy is underway. A new therapy based on using the body's natural immune defences is having unprecedented success. But diagnostics, especially biomarkers are desperately needed to help select the right therapy.

The technology is moving faster than the market. The impact on the health care industry is enormous. Tumor Mutational Burden? Checkpoint Inhibitors? Cytokines? Find out about the technology in readily understood terms that explain the jargon. Find opportunities and pitfalls. Understand growth expectations and the ultimate potential market size.

Key Topics Covered:

1. Introduction and Market Definition
1.1 What are Immuno-Oncology Diagnostics?
1.2 Immuno-oncology - the looming cure
1.2.1 Immuno-oncology Diagnostics Takes a Leading Role
1.3 Market Definition
1.3.1 Market Size
1.3.2 Currency
1.3.3 Years
1.4 Methodology
1.5 U.S. Medical Market and laboratory Testing - Perspective

2. Immunotherapy - Guide to Immune Technologies
2.0 The Immune System
2.0.1 Innate immune system
2.0.1.1 Surface barriers
2.0.1.2 Inflammation
2.0.1.3 Complement system
2.0.1.4 Cellular barriers
2.0.1.5 Natural killer cells
2.0.2 Adaptive immune system
2.0.2.1 Lymphocytes
2.0.2.2 Killer T cells
2.0.2.3 Helper T cells
2.0.2.4 Gamma delta T cells
2.0.2.5 B lymphocytes and antibodies
2.0.3 Tumor immunology - the immune surveillance system
2.1 Immuno OncologyDiagnostics
2.1.1 Checkpoint Assays
2.1.1.1 Outlook for Checkpoint Assays
2.1.2 Cytokine Assays
2.1.2.1 Outlook for Cytokine Assays
2.1.3 Genomic Germline
2.1.3.1 Outlook for Genomic Germline
2.1.4 Genomic Tumour
2.1.4.1 Outlook for Genomic Tumour
2.1.5 Tumor Microenvironment
2.1.5.1 Outlook for Tumor Micro Environment
2.1.6 Others
2.1.6.1 Outlook for Other Diagnostics

3. Industry Overview
3.1 Players in a Dynamic Market
3.1.1 Academic Research Lab
3.1.2 Diagnostic Test Developer
3.1.3 Genomic Instrumentation Supplier
3.1.3.1 Cell Separation and Viewing Instrumentation Supplier
3.1.4 Pharmaceutical/Reagent Supplier
3.1.5 Independent Testing Lab
3.1.6 Public National/regional lab
3.1.7 Hospital lab
3.1.8 Physician Lab
3.1.9 Audit Body
3.1.10 Certification Body

4. Market Trends
4.1 Factors Driving Growth
4.1.1 Outcome potential
4.1.2 Companion Diagnostics
4.1.3 Funding
4.1.4 Technology Environment
4.1.5 Target Solutions
4.2 Factors Limiting Growth
4.2.1 Complex Role of Diagnostics
4.2.2 Clinical Trials Role
4.2.3 Protocols
4.3 Diagnostic Technology Development
4.3.1 Combinations - Issues and Complexity
4.3.2 Shifting Role of Diagnostics
4.3.3 Multiplexing and Foundation One
4.3.4 The Disruption Dynamic
4.3.5 The Race for Biomarkers
4.3.6 The Next Five Years

5. Cancer Immunotherapy Recent Developments
5.1 Recent Developments - Importance and How to Use This Section
5.1.1 Importance of These Developments
5.1.2 How to Use This Section

Novigenix and BioLizard to develop NGS Based Diagnostic Algorithm
Biodesix and Immodulon Collaborate for Pancreatic Cancer Treatment
Generex to Merge with NuGenerex Immuno-Oncology
Cellgen Diagnostics and Genomic Testing Cooperative Partner to Develop
Companion Diagnostics for Cancer Therapies
Hematogenix Launches FDA Approved Immuno-oncology Test for Triple-Negative
Breast Cancer
Icon Acquires MolecularMD
Guardant Health to Develop Companion Diagnostic Tests for AstraZeneca
Tumor Mutational Burden as Predictor of Immunotherapy Success
Foundation Medicine and Merck to Develop Diagnostic Tests for Keytruda
Abcam Acquires Calico Biolabs
Cancer Genetics and NovellusDx to Merge
ApoCell Expands Immuno-Oncology Biomarker Services
MRM Proteomics Inc and Exactis Innovation Partner
Agilent Companion Diagnostic Gains FDA Approval in Urothelial Carcinoma
Fluidigm Partners with GenomOncology to Provide Immuno-Oncology Solution
MolecularMD Launches Validated Tumor Mutation Burden Assay
Minomic Secures Key Patent in the United States and China
Biocartis and Wondfo Announce Joint Venture
Five Prime Therapeutics Announces Collaboration with Roche to Develop
Companion Diagnostics
Cancer Genetics Expands Immuno-Oncology Panel
10x Genomics Acquires Epinomics, To Launch ATAC-Seq Product
Qiagen, Freenome Partner to Improve Companion Diagnostic Development
Personal Genome Diagnostics to Develop Companion Diagnostic for Five Prime
Thermo Fisher Expands Oncomine Immuno-Oncology Assay Portfolio
Bristol-Myers Squibb and Illumina to Develop Companion Diagnostics for Oncology
Immunotherapies
HalioDx announces high capacity IHC multiplex technology
MolecularMD to Implement Promega's Technology
NCI, NanoString Collaborate to Evaluate Utility of PanCancer Gene Expression Panel
MIODx to Develop Immune Repertoire Sequencing Assay to Predict Immunotherapy
Response
Personal Genome Diagnostics Licenses Tumor Mutation Burden from MSKCC
HalioDx Closes 18.5M Series B Round
Announcement of the 2018 Nobel Prize in Physiology or Medicine

6. Profiles of Key Immunotherapy Companies

10X Genomics
Abbott Laboratories
Abcam
Adaptive Biotechnologies
Aethlon Medical
Agena Bioscience
Angle plc
Apocell
ARUP Laboratories
Beckman Coulter
Becton Dickinson
Bioarray Genetics
BioCartis
Biocept
Biodesix Inc
BioFluidica
BioGenex
bioMrieux
Bio-Rad
Bio-Techne
Bristol-Myers Squibb
Cancer Genetics
Caris Molecular Diagnostics
CellMax Life
Charles River Laboratories
Chronix Biomedical
Circulogene
Clearbridge BioMedics
Clinical Genomics
Cynvenio
Cytolumina Technologies Corp.
CytoTrack
Dako (Agilent)
Diagnologix LLC
Epic Sciences
Exosome Diagnostics
Fluidigm Corp
Fluxion Biosciences
Foundation Medicine
Freenome
Genomic Health
GenomOncology
GRAIL
Guardant Health
HalioDx
Horizon Discovery
HTG Molecular Diagnostics
iCellate
Illumina
Incell Dx
Inivata
Integrated Diagnostics
Invivoscribe
Leica Biosystems
Luminex
MDx Health
Merck & Co., Inc
MIODx
Molecular MD
MRM Proteomics Inc
Myriad Genetics/Myriad RBM
Nanostring
Natera
Neogenomics
New Oncology
Oncocyte
Ortho Clinical Diagnostics
Perkin Elmer
Personal Genome Diagnostics
Pfizer
Promega
Protagen Diagnostics
Qiagen
Quanterix
Rarecells SAS
Roche Diagnostics
Siemens
Silicon Biosystems
SkylineDx
SRI International
Sysmex
Thermo Fisher
Trovagene
Vortex Biosciences

7. Global Market Size
7.1 Immuno-oncology Diagnostics Global Market Size by Country with Charts
7.2 Immuno-oncology Diagnostics Global Market Size by Type with Charts

8. Global Market by Type
8.1 Checkpoint Assay Market
8.1.1 Checkpoint Assay Market by Country with Chart
8.2 Cytokine Assay Market
8.2.1 Cytokine Assay Market by Country with Chart
8.3 Genome Germline Market
8.3.1 Genome Germline Market by Country with Chart
8.4 Genome Tumour Market
8.4.1 Genome Tumour Market by Country with Chart
8.5 Tumour Micro Environment Market
8.5.1 Tumour Micro Environment Market by Country with Chart
8.6 Other Market
8.6.1 Other Market by Country with Chart

9. Appendices
9.1 FDA Cancer Drug Approvals by Year
9.2 Clinical Trials Started 2010 to 2016
9.3 Prevalence of Cancer Treatments - 2015

For more information about this report visit https://www.researchandmarkets.com/r/erc6gz

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets